Abstract Details

Title Safinamide, a New Anti-Parkinson Agent Is Effective and Well-Tolerated in Early PD Patients on a Stable Dose of a Single DA-Agonist: Results of a Randomized, International, Placebo-Controlled, Phase III Trial

Topic Movement Disorders

Presentation(s) (-)

Poster/Presentation
Number 001

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Fabrizio Stocchi	Fabrizio Stocchi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bial, Biogen, Sunovion, Lundbeck, UCB, Zambon, Chiesi, Lusofarmaco, Abbvie, Neuroderm, Kyowa, Synegile, Roche, Britannia, Sunovion, Blue Rock. Fabrizio Stocchi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIAL, Zambon, Biogen, Roche, Synegile, Sunovion. Fabrizio Stocchi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bial, Zambon, UCB, Kyowa, Sunovion.
Cecilia Vidal, MD (Hospital Pro Cardiaco)	No disclosure on file
Rupam Borgohain, MD	No disclosure on file
Marco Onofrj, MD	Dr. Onofrj has nothing to disclose.
	No disclosure on file
Laurie M. Douglass, MD (Boston Medical Center)	No disclosure on file
Mohit Bhatt, MD, MBBS	No disclosure on file
Stefano M. Rossetti, MD (Rossetti Consulting Sas)	No disclosure on file
Ravi Anand (Novartis Pharmacueticals)	No disclosure on file
Pablo Lorenzana-Pombo, MD	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��